Experience

Oryzon Genomics SA

• Spain
• Biotechnology
• 1 - 100 Employee

• Platform Leader of Biochemistry and Assay Development

  • Dec 2022 - Present



Moirai Biodesign

• Spain
• Biotechnology Research
• 1 - 100 Employee

• Research Scientist - Marie Skłodowska-Curie Fellow (TECNIOSpring+, ACCIÓ)

  • Mar 2019 - Aug 2022

  RNA-based diagnostics and therapeutics. CTO (supervisor): Ivan Dotu • Envision, design and test novel RNA-based tools for detection of bacterial strains and viruses: - Develop and implement 'Plug & Play RNA' technology as a diagnostic tool for bacterial and viral infections. - Optimize fluorescent RNA aptamer technology as a novel tool for sepsis and SARS-CoV-2 detection. • Co-lead (with the CTO) Moirai's AI-based program on RNA design and RNA structure-function studies. • Coordinate Technology team research development: day-by-day experimental design, research goals and direction and novel R+D projects regarding RNA-based diagnostics and therapeutics. • Project managing, research planning and patent and grant writing, including but not limited to: - Marie Skłodowska-Curie Fellowship/ TECNIOSpring program, ACCIÓ (Generalitat de Catalunya) - EIC PathFinder Challenge program and Open proposals (European Innovation Council, EIC, EU) • Preparation and implementation of new Standard Operation Procedures (SOP). • Support Product Development team on isothermal amplification, and RNA isolation from bacteria in blood. Show less



Memorial Sloan Kettering Cancer Center

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Research Associate

  • May 2017 - Feb 2019

  Michael G. Kharas lab. Molecular Pharmacology Program, Sloan-Kettering Institute, MSKCC.• Project managing, research planning and grant writing (including private and public Funding Agencies and grants such as R01 from the United States Government).• Coordination of drug discovery research project with Tri-Institutional Therapeutics Discovery Initiative (TDI) (Rockefeller University, Weill Cornell Medicine-Cornell University & MSKCC) and pharmaceutical companies (e.g. Takeda Pharmaceuticals).• Trained and mentored interns and graduate students (Sloan-Kettering Institute and Cornell University). Show less

• Research fellow

  • Apr 2012 - Apr 2017

  Michael G. Kharas lab. Molecular Pharmacology Program, Sloan-Kettering Institute, MSKCC.• Implemented a Fluorescence Polarization (FP) and AlphaScreen assay to screen for modulators of RNA-binding activity of MUSASHI (MSI) family and other RNA-binding proteins (RBPs) involved in leukemia.• Established biophysical/ biochemical assays to study small-molecule interaction mechanisms to RNA and RBPs.• Developed fluorescence and chemiluminescent shift-assays (EMSA) to assess RNA-binding activity inhibition. • Obtained a 1.7Å X-ray diffraction crystal of MSI2 RNA-recognition motif 1 (RRM1), helped docking small-molecules in the RNA-binding site and validated interaction(s) by mutagenesis, NMR analysis and cell-based assays.• Assessed in vitro and in vivo activity of small molecules targeting RBPs in leukemia cellular and mouse models. Show less



IrsiCaixa AIDS Research Institute

• Spain
• Research Services
• 1 - 100 Employee

• Postdoctoral Fellow

  • Jul 2009 - Mar 2012

  Mentor(s): Javier Martinez-Picado (IrsiCaixa) and Marçal Pastor-Anglada (UB)• Studied efflux transporters (P-gp and MRPs) and single nucleotide polymorphisms (SNPs) involved in antiviral drug disposition (HIV integrase inhibitors -INIs- and nucleoside-reverse transcriptase inhibitors, NRTIs) and response.• Trained and mentored a graduate student in SNP studies in HIV resistance and the generation of stable cell lines (i.e. 293 and CHO cells) expressing drug transporters and mutants.

• PhD in Immunology & Cell Biology

  • Oct 2004 - Jun 2009

  PhD mentor: Javier Martinez-Picado. Retrovirology and Clinical Studies Lab.• Used IHQ, absolute quantitative real-time qPCR assays and western blot to quantify levels and expression of Nucleoside Transporters (NTs) and Organic Transporters (OCTs and OATs) in CD4+ T-cells and monocyte-derived macrophages (MDMs).• Studied the effect of Human Immunodeficiency Virus (HIV) drug transporters levels and activity in RNA viruses’ infection, viral replication and resistance (including HIV and Hepatitis C Virus -HCV-).• Coordination of research projects with the PI and pharmaceutical companies (Raltegravir project; Merck & Co).• Project managing (including budget preparation), fellowship and grant writing. Show less



Universitat de Barcelona

• Spain
• Research Services
• 700 & Above Employee

• Research collaborator

  • Oct 2004 - Mar 2012

  Molecular Pharmacology and Experimental Therapeutics Lab Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain. Principal Investigator (PI): Marçal Pastor-Anglada. • Radiolabeled measurement of binding and transport of [3H]- and [14C]-labeled antiviral drugs in stable expressing adherent cell lines (e.g. HEK293 and CHO) and in suspension cancer cells (e.g. CCRF-CEM or MOLM13). Molecular Pharmacology and Experimental Therapeutics Lab Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain. Principal Investigator (PI): Marçal Pastor-Anglada. • Radiolabeled measurement of binding and transport of [3H]- and [14C]-labeled antiviral drugs in stable expressing adherent cell lines (e.g. HEK293 and CHO) and in suspension cancer cells (e.g. CCRF-CEM or MOLM13).



The Julius Maximilians University of Würzburg

• Germany
• Higher Education
• 700 & Above Employee

• Predoctoral stay (9-months)

  • Feb 2007 - Oct 2007

  Hermann Koepsell's lab. Julius-von-Sachs-Institute of Biosciences, University of Würzburg, Germany • Evaluated the role of human Organic Cation Transporters (hOCTs) in the uptake mechanism of HIV NRTIs by the use and optimization of short-time radiolabeled uptake measurements in CHO cells and Xenopus laevis oocytes. Hermann Koepsell's lab. Julius-von-Sachs-Institute of Biosciences, University of Würzburg, Germany • Evaluated the role of human Organic Cation Transporters (hOCTs) in the uptake mechanism of HIV NRTIs by the use and optimization of short-time radiolabeled uptake measurements in CHO cells and Xenopus laevis oocytes.